DK1626974T3 - Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister - Google Patents

Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister

Info

Publication number
DK1626974T3
DK1626974T3 DK04759767T DK04759767T DK1626974T3 DK 1626974 T3 DK1626974 T3 DK 1626974T3 DK 04759767 T DK04759767 T DK 04759767T DK 04759767 T DK04759767 T DK 04759767T DK 1626974 T3 DK1626974 T3 DK 1626974T3
Authority
DK
Denmark
Prior art keywords
estrogen receptor
receptor beta
beta agonists
selective estrogen
substituted benzopyrans
Prior art date
Application number
DK04759767T
Other languages
Danish (da)
English (en)
Inventor
Gregory Lee Durst
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1626974T3 publication Critical patent/DK1626974T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK04759767T 2003-04-21 2004-04-08 Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister DK1626974T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46440403P 2003-04-21 2003-04-21
PCT/US2004/009272 WO2004094400A2 (en) 2003-04-21 2004-04-08 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (1)

Publication Number Publication Date
DK1626974T3 true DK1626974T3 (da) 2008-11-17

Family

ID=33310882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04759767T DK1626974T3 (da) 2003-04-21 2004-04-08 Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister

Country Status (17)

Country Link
US (3) US7442812B2 (sl)
EP (1) EP1626974B1 (sl)
JP (1) JP4481300B2 (sl)
CN (1) CN100374444C (sl)
AT (1) ATE406373T1 (sl)
AU (1) AU2004232798B2 (sl)
BR (1) BRPI0409588A (sl)
CA (1) CA2518819A1 (sl)
CY (1) CY1110443T1 (sl)
DE (1) DE602004016150D1 (sl)
DK (1) DK1626974T3 (sl)
ES (1) ES2311838T3 (sl)
MX (1) MXPA05011243A (sl)
PL (1) PL1626974T3 (sl)
PT (1) PT1626974E (sl)
SI (1) SI1626974T1 (sl)
WO (1) WO2004094400A2 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789421A1 (en) 2004-07-19 2007-05-30 Janssen Pharmaceutica N.V. Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors
CA2578164A1 (en) 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
ES2361031T3 (es) * 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
JP2006232727A (ja) * 2005-02-24 2006-09-07 Chisso Corp クマリン誘導体、この化合物を含有する液晶組成物およびこの液晶組成物を含有する液晶表示素子
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
CN109134493A (zh) * 2018-09-19 2019-01-04 浙江师范大学 一种具有抗菌活性的2-氧代色烯并噻吩衍生物及其合成方法和应用
CN109400564B (zh) * 2018-09-25 2021-03-12 信阳师范学院 一种含三氟甲基的苯并二氢吡喃-4-酮类化合物及其制备方法
CN110128393B (zh) * 2019-06-21 2022-09-30 华侨大学 一种取代异香豆素衍生物的制备方法
CN112898263B (zh) * 2021-01-28 2022-03-08 江西中医药大学 一种从佛手中分离的香豆素骈木脂素化合物及其保肝用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0792292T4 (da) 1995-09-08 2009-07-20 Karobio Ab Orphan-receptor
WO1999002512A1 (en) 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
EP1163225A1 (en) 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6518301B1 (en) 1999-04-16 2003-02-11 Astrazeneca Ab Estrogen receptor-β ligands
DK1246814T3 (da) 1999-12-30 2005-05-30 Signal Pharm Llc Forbindelser og fremgangsmåder til modulation af östrogenreceptorer
WO2001064665A1 (en) * 2000-03-01 2001-09-07 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
EP1272471B1 (en) 2000-03-27 2007-10-03 N.V. Organon Non-steroidal, tetracyclic compounds for estrogen-related treatments
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
WO2003015805A1 (en) 2001-08-13 2003-02-27 Michael Hargreaves Riley Composition for removal of toxins
CA2467013C (en) * 2001-11-19 2010-08-10 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
DE602004025460D1 (de) * 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
ES2361031T3 (es) * 2004-10-18 2011-06-13 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists

Also Published As

Publication number Publication date
US7842822B2 (en) 2010-11-30
CA2518819A1 (en) 2004-11-04
CN1777614A (zh) 2006-05-24
DE602004016150D1 (de) 2008-10-09
US7585985B2 (en) 2009-09-08
CY1110443T1 (el) 2015-04-29
BRPI0409588A (pt) 2006-04-18
AU2004232798B2 (en) 2010-04-22
ES2311838T3 (es) 2009-02-16
MXPA05011243A (es) 2005-12-15
CN100374444C (zh) 2008-03-12
PT1626974E (pt) 2008-11-14
US20090298925A1 (en) 2009-12-03
EP1626974B1 (en) 2008-08-27
JP4481300B2 (ja) 2010-06-16
US7442812B2 (en) 2008-10-28
EP1626974A2 (en) 2006-02-22
US20080312312A1 (en) 2008-12-18
JP2006524240A (ja) 2006-10-26
WO2004094400A3 (en) 2005-02-24
PL1626974T3 (pl) 2009-01-30
AU2004232798A1 (en) 2004-11-04
ATE406373T1 (de) 2008-09-15
WO2004094400A2 (en) 2004-11-04
SI1626974T1 (sl) 2009-02-28
US20070106082A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
IL185867A0 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
ATE432280T1 (de) Imidazopyridinderivate als melanocortinrezeptoragonisten
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
ES2243579T3 (es) Derivados de pirazolopirideno.
AR028579A1 (es) Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
ATE394386T1 (de) 2-phenylpyran-4-on-derivate als selektive cox-2 inhibitoren
UY27406A1 (es) Derivados de 2h-1-benzopirano, procesos para su preparación y composiciones farmacéuticas que los contienen